Evidence map›Paper›PMID 33789763›Full record

ArticleExperimental hematology & oncology2021

Evaluation of acute myeloid leukemia blast percentage on MethylC-Capture Sequencing results.

Erna Yang, Desheng Gong, Wei Guan, Jieying Li, Xuefeng Gao, Yonghui Li, Li Yu

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology & oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Erna YangDepartment of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China.
Desheng GongDepartment of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China.
Wei GuanDepartment of Hematology, Chinese PLA General Hospital, Beijing, 100853, China.
Jieying LiDepartment of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China.
Xuefeng GaoCentrol Laboratory, Shenzhen University General Hospital, Shenzhen University Health Science Center, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China. xfgao@szu.edu.cn.
Yonghui LiCentrol Laboratory, Shenzhen University General Hospital, Shenzhen University Health Science Center, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China. yonghuili@szu.edu.cn.
Li YuDepartment of Hematology and Oncology, International Cancer Center, Shenzhen Key Laboratory of Precision Medicine for Hematological Malignancies, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Shenzhen University Health Science Center, Shenzhen University, Xueyuan AVE 1098, Nanshan District, Shenzhen, Guangdong, 518000, People's Republic of China. yuli@szu.edu.cn.
Shenzhen University Health Science Center · CNChinese PLA General Hospital · CN

Funding

"Major New Drug Development Project" from Ministry of Science and Technology of China 2019ZX09201-002-003National Major Science and Technology Projects of China 82030076National Natural Science Foundation of China 81870134National Natural Science Foundation of China 81970151National Natural Science Foundation of China 82070161Natural Science Foundation of Beijing Municipality 7202186Natural Science Foundation of Shenzhen University General Hospital SUGH2020QD008
6 · The paper itself

Abstract

Aberrant DNA methylation is often related to the diagnosis, prognosis, and therapeutic response of acute myeloid leukemia (AML); however, relevant studies on the relationship between bone marrow myeloblast percentage and the DNA methylation level in AML have not been reported. We evaluated the effects of AML blast percentage on DNA methylation level using the MethylC-capture sequencing (MCC-Seq) approach based on next-generation sequencing (NGS) and found that the methylation level of both genome-wide and promoter regions significantly increased when the percentage of AML blasts reached ≥ 40%, indicating that an accurate DNA methylation level in cancer cells can be obtained when the bone marrow samples of AML patients have more than 40% myeloblasts.

Indexed as

AMLBlast percentageMCC-SeqMethylation status

Identifiers

PMID33789763
PMCPMC8011402
OpenAlexW3150423766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.